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Interventional Treatment Options 
for Trigeminal Neuralgia
Yashar Eshraghi, Sarah J. Vitug and Maged Guirguis
Abstract
Trigeminal neuralgia is characterized by sudden and severe shock-like episodes 
of transient unilateral pain in the trigeminal nerve distribution. Most cases are 
idiopathic and are known to respond favorably to anticonvulsants. For patients who 
fail at least three drug trials or experience intolerable side effects, surgery may be 
warranted. First, a diagnostic block at the trigeminal nerve or Gasserian ganglion to 
confirm clinical diagnosis is performed. Surgical intervention can be either ablative 
or nonablative, each with its respective indications, contraindications, and risk-
benefit profile. Most common are the percutaneous rhizotomies: conventional and 
pulsed radiofrequency ablation (RFA), chemical glycerol injections, and mechani-
cal balloon compression. Stereotactic or gamma knife radiosurgery (GKRS) is the 
least invasive with only a moderate duration of pain relief, whereas microvascular 
decompression (VMD) is the most invasive, but associated with greatest long-term 
benefit. RFA has consistently shown favorable results and is the only modality 
with evidence of pain relief in ≥50% of patients treated 20 years postoperatively. 
Auxiliary interventional options such as peripheral neurectomy, botulinum toxin 
type-A (BTX-A) injections, and cryotherapy are available for those with contraindi-
cations to rhizotomies, radiosurgery, or neurosurgery. Ultimately, physicians must 
tailor their management of trigeminal neuralgia to the needs of the patient.
Keywords: trigeminal neuralgia, Meckel’s cave, Gasserian ganglion, ophthalmic 
division, maxillary division, mandibular division, classic approach, coronoid 
approach, trigeminal nerve block, Gasserian ganglion block, percutaneous 
radiofrequency rhizotomy, percutaneous glycerol rhizotomy, percutaneous balloon 
compression, stereotactic radiosurgery, gamma knife radiosurgery, microvascular 
decompression, peripheral neurectomy, botulinum toxin type-A, cryotherapy, 
cryoanalgesia
1. Introduction
Trigeminal neuralgia, also known as “tic douloureux,” is characterized by 
distinctive, transient episodes of unilateral lancinating pain in the trigeminal nerve 
distribution [1]. Most often, etiology is unknown and is not attributed to another 
disorder. This presentation is referred to as Type I or classic trigeminal neuralgia. 
Inflammatory causes (e.g., multiple sclerosis, infection, etc.), compression of the tri-
geminal roots (e.g., tumors and arteriovenous malformation), abnormalities of the 
skull base [2], or pain due to underlying disease processes comprise Type II or sec-
ondary trigeminal neuralgia. Atypical or mixed trigeminal neuralgia is when patients 
experience sensory loss or dull, burning pain in the trigeminal nerve distribution in 
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between the characteristic paroxysms [2], and often without an identifiable trigger 
zone. Atypical disease is more commonly associated with a symptomatic presenta-
tion or background pain of milder intensity for up to 50% of the time [3].
Patients usually describe the pain as sudden and severe electric, shooting or 
shock-like, and superficial pain lasting anywhere from a few seconds to several 
minutes [2]. Attacks are considered paroxysmal, where frequency of episodes can 
range from a few to several dozens in 1 day [3]. Additionally, paroxysms are gener-
ally similar in nature for individual patients. The pain associated with the classic 
presentation can be precipitated by light mechanical stimulation to the face or oral 
mucosa (e.g., facial hair grooming and tooth brushing) or by thermal stimulation 
(e.g., cold or heat exposure) [2]. It is common for patients to develop an aversion to 
eating, drinking, or previous noxious stimuli for fear of triggering another episode. 
More so, the psychological impact may cause patients to appear distressed or 
anxious during physical examination [4]. For these reasons, the unique presentation 
with the absence of other neurologic abnormalities makes trigeminal neuralgia a 
clinical diagnosis [2]. Dental X-rays or MRIs may be warranted to clarify differen-
tial diagnoses or confirm a suspected etiology which may guide management.
Overall, trigeminal neuralgia is considered a rare disease according to popula-
tion-based studies, with estimated 4–13 cases diagnosed per 100,000 individuals 
each year [5]. However, regional biases exist where countries with less stringent 
diagnostic criteria yield a higher incidence. For example, the annual incidence 
of disease in the United Kingdom (26.8 per 100,000 cases) is based off general 
practitioner lists and fewer diagnostic criteria, compared to the United States (5.9) 
and Netherlands (12.6), respectively [3].
Anatomically, the vast majority of cases affect either the maxillary or mandibu-
lar division (V2 or V3), alone or in combination. In approximately 5% of patients, 
the symptoms occur solely in the ophthalmic division (V1). In terms of disease 
onset, trigeminal neuralgia rarely manifests in individuals younger than age 40, 
with incidence peaking in the elderly and more than twice as many women affected 
than men [6]. However, it is important to note that trigeminal neuralgia is con-
sidered a progressive disease with symptomatic treatment with repeat procedures 
becoming less effective over time [3].
2. First-line management of medication-resistant trigeminal neuralgia
The primary treatment for trigeminal neuralgia is pharmacologic. Pain associ-
ated with trigeminal neuralgia responds poorly to analgesics and favorably to 
antiepileptic drugs. First-line medical treatment is carbamazepine, with other 
adjuncts such as phenytoin, gabapentin, lamotrigine, or baclofen added for 
persistent pain [4].
Patients with intolerable medication side effects or who experience pain refrac-
tory to three attempted drug trials and are surgically fit as dictated by medical 
status/age may be considered for surgery [7]. Patients may first undergo prelimi-
nary nerve blocks either at the level of a trigeminal nerve branch or at the Gasserian 
ganglion to confirm the diagnosis of trigeminal neuralgia. If patients experience 
pain relief with this diagnostic procedure, patients may elect further therapeutic 
treatment with the same modality or discuss different surgical treatment options 
with their neurologist, neurosurgeon, anesthesiologist, or other physicians involved 
in their care [8].
Surgical methods for the treatment of trigeminal neuralgia can be separated 
into four broad categories—peripheral lesions to the terminal branches, lesions to 
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radiosurgery or gamma knife radiosurgery (GKRS), and posterior fossa interven-
tion with microvascular decompression (MVD) [9]. Alternatively, surgical inter-
vention can be divided into non-ablative/nondestructive (MVD) and ablative (all 
other surgical interventions).
The non-ablative MVD is a complex posterior fossa procedure requiring a cra-
niotomy and thus is performed exclusively by neurosurgeons [10]. This approach is 
rapidly becoming the surgical intervention of choice when there is MRI-confirmed 
vascular compression by the nerve root as pain relief is significant, and severe 
complication risks such as death and relapse rate are among the lowest of all surgi-
cal treatment modalities [3]. If no compression is found, percutaneous rhizotomies 
via thermal (pulsed radiofrequency or thermocoagulation), chemical (glycerol), 
or mechanical (balloon compression) techniques or gamma knife radiosurgery 
(GKRS) are preferred. As sensory ablation by rhizotomy demonstrate similar 
pain relief results in comparison to MVD, it is important for patients to consider 
the slightly higher risk of complications and slightly lower patient satisfaction at 
5-year follow-up with rhizotomies [10]. GKRS is also a safe and effective treatment; 
however, patients are counseled on the likelihood of a delayed onset of pain relief 
following treatment, and those with a significant surgical history involving the 
head may make poor candidates for GKRS [9].
3. Second-line management of medication-resistant trigeminal neuralgia
Ultimately, patient preferences for surgical intervention are always taken into 
consideration and only if medical status permits. For patients who wish to undergo 
intervention for management of their medically refractory disease and do not 
wish to have MVD, any form of rhizotomy, or GKRS, patients may elect to have 
other treatments such as peripheral neurectomy, botulinum toxin type-A (BTX-A) 
injections, or cryotherapy. Such interventions can be administered by a variety of 
physicians such as oral and maxillofacial surgeons, anesthesiologists, neurologists, 
and other certified providers in both inpatient and outpatient settings.
Peripheral or mental neurectomy under local anesthesia is still offered for man-
agement of pharmacologically resistant trigeminal neuralgia; however, it is most often 
used in rural areas where more advanced surgical options (MVD, rhizotomy, GKRS) 
are unavailable or unaffordable [11]. Neurectomies essentially are too underreported 
to gauge its actual utility compared to other treatments. BTX-A is another minimally 
invasive approach, which can be performed in an outpatient setting and repeated a 
number of times without significant adverse effects. However, the location (intrader-
mal or intramuscular) and dosage (25–75 units) per injection have yet to be standard-
ized [12]. Anecdotally, cryotherapy is one of the more painful procedures and does 
not appear to have significant long-term efficacy in pain relief compared to other 
interventions. It is maintained that cryogenic insult varies with nerve diameter and is 
thus associated with variable nerve regeneration and shorter pain-free intervals [13].
Often, patients electing these auxiliary interventions have major contraindi-
cations for neurosurgery, are unfit for general anesthesia, or simply prefer less 
invasive procedures [14–16]. However, the effectiveness, duration of pain relief, rate 
of relapse and complication, and overall patient satisfaction with auxiliary inter-
ventions are generally based on case reports and studies with small sample sizes; 
thus, overall impression of such modalities is less favorable compared to MVD, 
rhizotomy, and GKRS [17].
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4. Complications
As with any invasive procedure, patients must be counseled on postoperative 
risk for infection and bleeding (hematomas) at the site of needle entry or incision. 
With trigeminal nerve and Gasserian ganglion blocks, a small risk of dysesthesias or 
a loss of consciousness may occur if CSF is inadvertently injected with local anes-
thetic [8]. For patients undergoing MVD, rhizotomy procedures, or GKRS, postop-
erative hyperesthesia, facial asymmetry, masseter weakness, alteration in corneal 
sensation, and meningitis are extremely rare complications; however, patients 
must always be informed of potential risks [8]. As with the auxiliary intervention 
options, patients are educated on the similar complications such as dysesthesias, 
facial weakness, and asymmetry, albeit rare. Of note, cryotherapy is one technique 
that attempts to preserve sensation post-procedure.
5. Conclusion
It is imperative that patients accurately assess pain levels before and after sur-
gical intervention to better guide treatment options in the future if relapse occurs. 
Patients must understand that most of these surgical interventions may not rid 
their symptoms of trigeminal neuralgia permanently and that large, randomized 
controlled trials are needed to thoroughly predict the long-term efficacy of these 
interventions and disease prognosis. The paucity of standardization in the follow-
up period for patients undergoing surgical treatment is generally physician-
specific and on a case-by-case basis, depending on the severity of disease and 
wishes of the patient. However, the consensus in the literature is that surgical 
management for the treatment of medication-refractory trigeminal neuralgia is 
safe and effective.
5.1  Trigeminal (Gasserian) ganglion, maxillary nerve, and mandibular nerve 
blocks
Gasserian ganglion, maxillary nerve, and mandibular nerve blocks play an inte-
gral role as a diagnostic block prior to trigeminal neurolysis, if indicated. Patients 
who report significant pain reduction (greater than 50% compared to preoperative 
baseline) from two consecutive diagnostic blocks are recommended subsequent 
percutaneous procedures for a more sustained therapeutic effect.
5.1.1 Gasserian ganglion nerve block
5.1.1.1 Anatomy
The trigeminal nerve contains sensory and motor fibers. Somatic afferent fibers 
transmit pain, light touch, and temperature sensation from the skin of the face, the 
oral and nasal mucosa, the teeth, and the anterior two thirds of the tongue. Visceral 
efferent fibers innervate muscles of facial expression, the tensor tympani, and 
muscles of mastication. Also, the trigeminal nerve has multiple communications 
with autonomic nervous system through the ciliary, sphenopalatine, and optic and 
submaxillary ganglia.
The trigeminal nerve travels as follows: brain stem, prepontine fossa, Meckel’s 
cave (trigeminal/Gasserian ganglion location), and extracranial. The ganglion 
(approximately 1 × 2 cm) can be found within a reflection of dura mater known as 
Meckel’s cave, which lies in the middle cranial fossa adjacent to the petrous bone. 
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Superior to Meckel’s cave is the inferior surface of the temporal lobe, posterior is 
the brain stem, and medial is the cavernous sinus and internal carotid artery. After 
the Gasserian ganglion, the nerve separates somatotopically into the following 
divisions: ophthalmic (craniomedially), mandibular (caudolaterally), and maxil-
lary in between [8].
5.1.1.2 Indications
• Diagnostic block to confirm clinical diagnosis of trigeminal neuralgia [8]
• Therapeutic block in medically refractory cases
• Prognostic indicator for planned neuroablative or surgical procedure
• Diagnosis and management of various orofacial pain syndromes (e.g., cluster 
headache, persistent ocular pain, palliation of cancer pain)
5.1.1.3 Contraindications
The contraindications to Gasserian ganglion nerve block are the same as those 
for trigeminal nerve block: patient refusal, local infection, sepsis, coagulopathy, 
increased intracranial pressure, behavioral abnormalities, allergy to local anesthet-
ics, and lack of patient cooperation.
5.1.1.4 Approach
The patient is positioned supine with the cervical spine extended. As the 
patient’s cooperation is paramount, the procedure is usually done under local 
anesthetic and sedation [18]. Under fluoroscopic guidance, submental (Figure 1a) 
and lateral (Figure 1b) views are obtained to identify the foramen ovale [18]. 
Approximately 2.5 cm lateral to the corner of the mouth, a needle is advanced 
perpendicular to the pupil of the eye in a cephalad direction toward the auditory 
meatus. Once the needle tip has made contact with the base of the skull, the needle 
Figure 1. 
Submental (a) and lateral (b) view of needle in foramen ovale [18].
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is withdrawn slightly and walked posteriorly into the foramen ovale. The needle 
is carefully aspirated to confirm the absence of CSF/blood prior to therapeutic 
injection. After needle position is confirmed and aspiration is negative, an average 
volume of 0.4 mL of neurolytic solution is injected.
5.1.1.5 Complications
Due to the close relation between the Gasserian ganglion and the dural reflec-
tion, Meckel’s cave, inadvertent local anesthetic injection into CSF causing loss of 
consciousness is a feared complication of this procedure [19]. Additionally, dyses-
thesias [17] and hematoma formation upon needle entry into the foramen ovale are 
other complications associated with this technique.
5.1.1.6 Outcome
The overall therapeutic benefit of the Gasserian ganglion block is largely similar 
to that of trigeminal nerve block, with most patients reporting pain relief greater 
than 50% of baseline for up to 6–12 months [18] and much shorter duration if used 
as a diagnostic block.
5.1.2 Maxillary nerve and mandibular nerve blocks
5.1.2.1 Anatomy
The maxillary division (V2) is the second division of the trigeminal nerve, 
which exits the middle cranial fossa through the foramen rotundum, located at the 
roof of the pterygopalatine fossa (PPF) [8]. V2 provides purely sensory fibers to 
the lower eyelid, cheek, nares, upper lip, upper teeth, upper gums, nasal mucosa, 
palate, roof of the pharynx, maxillary sinus, ethmoid sinus, sphenoid sinus, and 
parts of the meninges.
Its branches are divided into four groups, depending on the location where they 
branch off: the cranium, the pterygopalatine fossa, the infraorbital canal, or the 
face [20]. The intracranial group includes the middle meningeal nerve [20]. The 
pterygopalatine group includes the zygomatic nerve, the superior alveolar nerves, 
the nasopalatine nerve, the palatine nerves, and the pharyngeal nerve [21]. The 
infraorbital group includes the infraorbital nerve and the anterior superior alveolar 
nerve [8]. The facial group includes the inferior palpebral nerve, the superior labial 
nerve, and the lateral nasal nerve.
The mandibular division (V3) is the third division of the trigeminal nerve, 
which exits the middle cranial fossa via the foramen ovale (≤1 cm in diameter), 
situated immediately dorsolateral to the pterygoid process [19]. V3 contains a 
large sensory root and a small motor root that provide innervation to the lower lip, 
lower teeth, gums, chin, jaw, parts of the external ear, and parts of the meninges. 
However, the mandibular division is known for providing motor innervation to the 
muscles of mastication.
Its branches are divided into three groups: the main trunk, the anterior division, 
and the posterior division [20]. The main trunk group includes efferent branches 
for the medial pterygoid, tensor tympani, tensor veli palatini muscles, and an affer-
ent nerve for the meningeal branch [20]. The anterior group includes the efferent 
masseteric, deep temporal, and lateral pterygoid nerves and the afferent buccal 
nerve [21]. The posterior group includes the efferent/afferent inferior alveolar nerve 
and the afferent auriculotemporal and lingual nerves.
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5.1.2.2 Indications
• Diagnostic block in assessment and management of trigeminal neuralgia and 
atypical facial pain [8]
• Anatomic differential neural blockade when more selective nerve block needed 
for diagnosis of various orofacial pain syndromes
• Therapeutic block for acute pain emergencies [18]
• Diagnosis and management of various orofacial pain syndromes (e.g., cluster 
headache, persistent ocular pain, palliation of cancer pain)
5.1.2.3 Contraindications
The contraindications for performing maxillary and mandibular nerve blocks 
include but are not limited to the following: patient refusal, local infection, sepsis, 
coagulopathy, increased intracranial pressure, behavioral abnormalities, allergy to 
local anesthetics, and lack of patient cooperation.
5.1.2.4 Approach
Patients are placed supine with cervical spine extended. The anesthesiologist 
should be at the patient’s side, approximately shoulder level. The site of needle 
puncture is medial to the masseter muscle (~3 cm lateral to the corner of the 
mouth) which can be identified by asking the patient to clench his or her teeth. 
Following the initial numbing, evidenced by the raised skin wheal, a 22-gauge, 
10-cm needle is inserted with fluoroscopic guidance [19]. Needle insertion is 
aligned with the pupil to a depth of 4.5–6 cm to contact the infratemporal surface 
of the greater wing of the sphenoid, immediately anterior to the foramen ovale 
[19]. The needle is then retracted and advanced into the foramen ovale to a final 
depth of 6–7 cm, often resulting in mandibular paresthesia, followed by paresthesia 
in the ophthalmic and maxillary nerve distribution with further needle advance-
ment. Injection of contrast will identify vascular uptake and extent of injectate 
spread [22]. Prior to injection with local anesthetic, the needle should be carefully 
aspirated to confirm the absence of CSF/blood. One millimeter of local anesthetic is 
generally adequate for a diagnostic nerve block to occur within 5–10 minutes.
The coronoid approach may be utilized for selective maxillary and mandibular 
nerve block. The coronoid notch is identified by asking the patient to open and close 
the mouth several times and palpating the area just anterior and slightly inferior 
to the acoustic auditory meatus. A needle is inserted just below the zygomatic arch 
directly in the middle of the coronoid notch and placement verified on lateral view 
(Figure 2a). The needle is advanced 2.5–5 cm in a plane perpendicular to the skull 
until the lateral pterygoid plate is encountered. Needle placement is verified on PA 
view (Figure 2b). Injection of contrast will identify vascular uptake and extent of 
injectate spread. The needle is withdrawn slightly, and an incremental injection 
technique of 3–5 mL of local anesthetic is administered to each nerve [22].
5.1.2.5 Complications
Hematoma formation upon needle entry into the foramen ovale and local 
anesthetic toxicity are the major complications associated with this procedure [22]. 
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However, dysesthesias, weakness of the muscles of mastication, secondary facial 
asymmetry, meningitis, intracranial hemorrhage with inadvertent intracranial 
needle placement, total spinal anesthesia, and anesthesia dolorosa are other compli-
cations associated with trigeminal nerve blocks [22].
5.1.2.6 Outcome
As a therapeutic block, effects of trigeminal nerve block are relatively short 
term, with most patients reporting pain relief greater than 50% of baseline for up 
to 6–12 months [18]. However, as trigeminal nerve blocks are primarily diagnostic, 
short-term pain relief is expected.
5.2  Interventional treatment for trigeminal neuralgia: percutaneous 
rhizotomies and neuromodulation
Peripheral lesions to the terminal branches with therapeutic intent are usually 
via radiofrequency thermocoagulation or highly concentrated alcohol injections 
[9] and less commonly with neurectomy, Botox injections, or cryolesions; however, 
adequate trials supporting these modalities are yet to surface [17].
Percutaneous lesions to the Gasserian ganglion are traditionally in the form 
of rhizotomies, radiofrequency, and chemical lesions by glycerol, phenol, or 
alcohol injection [18] but also via mechanical compression from balloon infla-
tion. Ganglion-level procedures are generally preferred as they are safer and more 
effective than peripheral techniques [23], as all procedures are carried out under 
fluoroscopic guidance [9].
5.2.1  Percutaneous radiofrequency rhizotomy (PRR): pulsed radiofrequency 
ablation and radiofrequency thermocoagulation
5.2.1.1 Indications
• Treatment of trigeminal neuralgia in a medically refractory or side-effect-
intolerable patient
Figure 2. 
Lateral view (a): needle inserted (white arrow) coaxially in coronoid notch. PA view (b): needle (white 
arrow) advanced medially until contact is made with lateral pterygoid plate [22].
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• High-risk operative patients such as the medically ill or elderly [24]
• Secondary trigeminal neuralgia due to multiple sclerosis [25]
• Diagnostic procedure in patients with atypical disease (constant or near 
constant pain in addition to the classic sharp stabbing pains in trigeminal nerve 
distribution) [26]
• Patient preference for minimally invasive procedure
5.2.1.2 Contraindications
Contraindications for PRR are patient refusal, local infection, sepsis, coagu-
lopathy, increased intracranial pressure, behavioral abnormalities, allergy to local 
anesthetics, and lack of patient cooperation. Radiofrequency thermocoagulation 
may be contraindicated in postherpetic neuralgia [25].
5.2.1.3 Approach
The patient is placed supine with cervical spine slightly extended. Procedure 
requires patient cooperation; thus, it is performed under local anesthetic and light 
sedation [18]. Under C-arm fluoroscopic guidance, a needle is introduced 2.5 cm 
lateral to the corner of the mouth. Advancement of the needle medial to the 
ramus of the jaw into the foramen ovale is verified on oblique view (Figure 3a). 
The use of bony landmarks and fluoroscopic guidance facilitates accurate radio-
frequency needle placement to locate Meckel’s cave through the foramen ovale. 
Needle placement is confirmed with lateral fluoroscopic view (Figure 3b) prior to 
neurolysis [24].
Through stepwise advancement of the needle toward the Gasserian ganglion, 
V3 is first encountered, followed by V2 and lastly V1 [26]. Once in Meckel’s 
cave, aspiration may yield CSF. The stylet is then replaced with the electrode to 
confirm that nerve root stimulation coincides with location of paresthesia felt by 
patient. Following accurate needle placement, the patient is anesthetized prior 
to thermal lesioning in cycles of 45–90 seconds at temperatures between 60 and 
90°C [26]. Other parameters have utilized 60-second cycles at 70°C [8]. Pulsed 
Figure 3. 
Oblique view (a) verifies needle placement medial to the ramus of the jaw prior to entry into the foramen 
ovale. Lateral view (b) confirms needle position prior to injuring the trigeminal nerve, a technique used with 
PRR, percutaneous glycerol rhizotomy (PGR), or percutaneous balloon compression (PBC) [24].
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radiofrequency is set to 42°C for 120-second cycles. Patient is awakened in between 
cycles for manual sensory testing throughout the face until complete pain resolu-
tion has been achieved.
5.2.1.4 Complications
Complications associated with PRR are decreased corneal sensation with 
increased risk of keratitis, masseter weakness, hyperesthesia, and although very 
rare, anesthesia dolorosa.
5.2.1.5 Outcome
Pain relief immediately following procedure is very high, with 97.6–99% of 
patients reporting full resolution. Pain relief was reported to be 61.8% at 1 year, 
57.7% at 5 years, 52.3% at 10 years, and 41% at 20 years. PRR appears to be the only 
surgical intervention with long-term follow-up at 20 years [24].
5.2.2 Percutaneous glycerol rhizotomy (PGR)
5.2.2.1 Indications
• Treatment of trigeminal neuralgia in a medically refractory or side-effect-
intolerable patient and other high-risk operative patients such as the medically 
ill or elderly [24]
• Patients who have previously undergone MVD or have history of multiple 
sclerosis [27]
• Diagnostic procedure in patients with atypical disease (constant or near con-
stant pain in addition to the classic sharp, stabbing pains in trigeminal nerve 
distribution) [26]
• Patient preference for a minimally invasive procedure
5.2.2.2 Contraindications
Contraindications to PGR are patient refusal, local infection, sepsis, coagu-
lopathy, increased intracranial pressure, behavioral abnormalities, allergy to local 
anesthetics, and lack of patient cooperation.
5.2.2.3 Approach
The patient is placed supine with the cervical spine slightly extended. 
Percutaneous techniques require patient cooperation during intermittent anesthe-
tization; thus, procedures are performed under local anesthetic and sedation [18]. 
Under C-arm fluoroscopic imaging, a needle is introduced 2.5 cm lateral to the 
corner of the mouth. The needle is inserted into the trigeminal cistern through the 
foramen ovale. Precise needle placement must be ascertained prior to puncture as 
subarachnoid entry beneath the temporal lobe may yield significant complications. 
CSF may be encountered when the needle contacts the Gasserian ganglion, unless 
patient has previously received surgical intervention in this area [26]. Radiopaque 
contrast is then utilized to visualize the cistern prior to glycerol gangliolysis. Patient 
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is repositioned to a sitting position for a test dose of sterile anhydrous glycerol, 
followed by dose escalation of 0.1–0.4 mL total. Patient must remain seated for 
approximately 2 hours postinjection [26].
5.2.2.4 Complications
Complications associated with PGR are hyperesthesia, decreased corneal sensa-
tion, facial hematoma, aseptic meningitis, hearing loss, bacterial meningitis, buccal 
mucosa penetration, and carotid puncture.
5.2.2.5 Outcome
Pain relief immediately following PGR is good, however, still below that from 
PRR and with greater variability; 71–97.9% of patients report full resolution 
immediately following procedure. Pain relief was reported to be between 53 and 
63% at 1 year and 43.5% at 5 years [24]. No further time points have been collected 
for PGR.
5.2.3 Percutaneous balloon compression (PBC)
5.2.3.1 Indications
• Treatment of trigeminal neuralgia in a medically refractory or side-effect-
intolerable patient and other high-risk operative patients such as the medically 
ill or elderly [24]
• Diagnostic procedure in patients with atypical disease (constant or near con-
stant pain in addition to the classic sharp, stabbing pains in trigeminal nerve 
distribution) [26]
• Patient preference for minimally invasive procedure
5.2.3.2 Contraindications
PBC may be relatively contraindicated in patients with underlying cardiac 
disease as trigeminal reflex bradycardia and hypotension may occur [28].
5.2.3.3 Approach
The patient is placed in a supine position with the neck and thorax slightly 
extended [29]. However, another approach involves the patient semi-seated with 
head retroflexed to obtain a submental vertical X-ray beam for a horizontal view 
of the foramen ovale [30]. Patient undergoes endotracheal intubation and general 
anesthesia. C-arm fluoroscopy is used for anteroposterior and lateral images to con-
firm needle placement. A 14-gauge needle is inserted approximately 2.5 cm lateral 
to the corner of the mouth, parallel to the sagittal plane to protect the oral mucosa. 
Under fluoroscopic guidance, the catheter is redirected to the foramen ovale. A no. 
4 Fogarty catheter is then advanced to 10–15 mm beyond the needle tip. The balloon 
is inflated until proximal to the posterior fossa with approximately 300 mg of I2/
mL iohexol [29]. Compression volume is patient specific, until pear-shaped balloon 
is achieved with respect to the nearby structures (e.g., clivus, sella, and petrous 
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bones). The contrast medium is aspirated, catheter is withdrawn, and pressure is 
applied to needle entry site.
5.2.3.4 Complications
Complications associated with PBC are hyperesthesia with persistent symptoms, 
masseter weakness, facial hematoma, hearing loss, anesthesia dolorosa, decreased 
corneal sensation, pseudoaneurysm, bacterial meningitis, septic meningitis, 
trigeminal reflex bradycardia, and hypotension.
5.2.3.5 Outcome
Pain relief immediately following PBC is also promising, however, still below 
that from PRR; 82–93.8% of patients report full resolution immediately following 
procedure. Pain relief was reported to be between 74.6% at 1 year, 69.8% at 5 years, 
and between 30 and 51.5% at 10 years [24]. No further time points have been col-
lected for PBC.
5.2.4 Stereotactic radiosurgery/gamma knife radiosurgery (GKRS)
5.2.4.1 Indications
• Patients who are surgically unfit for MVD due to significant medical 
comorbidities
• Patients who refuse to take anticonvulsants
• Patients currently on anticoagulation therapy [31]
5.2.4.2 Contraindications
As this noninvasive outpatient procedure is considered one of the safest surgical 
techniques in the treatment of trigeminal neuralgia, few contraindications have 
been reported. Patients who have had an extensive history of surgical intervention 
may be at an increased risk of complications [24].
5.2.4.3 Approach
The patient is supine with mild oral or intravenous sedation. A Leksell Model G 
stereotactic frame is secured to the patient’s head with local anesthetic [26]. MRI 
maps the neurovascular compression at the entry zone of the trigeminal nerve. 
Once exact intracranial location is confirmed, a 4-mm collimator is used, with 
radiation dose prescribed to 100% isodose line [32]. The isocenter is placed near the 
pars triangularis and highly focused beams of radiation (70–90 Gy) to the trigemi-
nal nerve root in the posterior fossa [7].
5.2.4.4 Complications
Complications of GKRS are dose dependent, with increased rate of occurrence 
rate with cumulative radiation dose exceeding 115 Gy. Alternatively, the rate of 
complications increases when GKRS is performed following failed treatment 
with other surgical interventions [24]. Hyperesthesias were reported in 6–42% of 
patients, and anesthesia dolorosa occurred at a rate of 0.2% [33].
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5.2.4.5 Outcome
Pain relief associated with GKRS can be delayed up to 8 weeks [9] postopera-
tively (mean time of 1 month) and is highly dependent on the accuracy of the 
stereotactic system used [7]. Between 79 and 91.8% of individuals had pain relief; 
however, a mean delay of 10 days to 3.4 months was experienced prior to initial pain 
relief. Further follow-ups identified 75–90% of patients with pain relief at 1 year, 
44–65% at 5 years, and 30–51.5% of individuals with pain relief at 10 years.
5.2.5 Microvascular decompression (MVD)
5.2.5.1 Indications
• Medically refractory patients who are deemed surgically fit as by medical 
status/age [7]
• First-line treatment in younger patients due to long-term improvement in 
quality of life [34]
5.2.5.2 Contraindications
Although advanced age is a relative contraindication, there is no age limit for this 
procedure as long as patients are fit to undergo general anesthesia [26].
5.2.5.3 Approach
The patient is placed in a lateral decubitus position, which allows for easier 
lumbar puncture and CSF drainage to decrease tension in infratentorial space. A 
suboccipital craniotomy is performed to enter the posterior fossa, targeting the 
trigeminal nerve-pons junction [26]. The infratentorial lateral supracerebellar 
approach accesses the trigeminal nerve within the superior portion of the cerebello-
pontine angle via the lateral aspect of the cerebellar tentorial surface [35]. Once the 
CSF is aspirated, retraction of the superolateral margin of the cerebellum facilitates 
contact with the nerve. Most commonly, the superior cerebellar artery (SCA) is 
responsible for nerve compression at the root entry zone and, less commonly, the 
anterior inferior cerebellar artery or superior petrosal veins [36]. Thus, the arach-
noid membrane must be dissected from the trigeminal nerve all throughout its 
course through Meckel’s cavity in order to expose the compression. The SCA courses 
medial to the trigeminal nerve, which always compresses the nerve medially. 
Retraction of the cerebellum should be minimized as injury to the vestibulocochlear 
nerve is at risk. For transposition of the compressing artery, the sling retraction 
technique is used [37].
5.2.5.4 Complications
Complications associated with MVD are trigeminal nerve deficit, facial weak-
ness, hearing loss, anesthesia dolorosa, aseptic meningitis, hydrocephalus, mortal-
ity, and cerebellar infarct or hematoma [24].
5.2.5.5 Outcome
Long-term pain relief from MVD has been found to be superior among exist-
ing surgical interventions for treatment of trigeminal neuralgia at this time; thus, 
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it is generally considered to be first-line intervention for operative candidates 
[24]. Between 80.3 and 96% of patients experienced initial pain relief immedi-
ately following MVD, 84% at 1 year, 72–85% at 5 years, and 74% at 10 years [24] 
(Tables 1 and 2).
Summary of complications
Procedure Complication Rate (%)
PRR Decreased corneal sensation; keratitis 5.7–17.3; 0.6–1.9 [38]
Masseter weakness 4 [39]
Hyperesthesia 3.3 [40]
Anesthesia dolorosa 0.6–0.8 [39]
PGR Hyperesthesia 23.3–72 [41]
Decreased corneal sensation 6.3–15 [40]
Facial hematoma 7 [42]
Aseptic meningitis 0.12–3 [42]
Hearing loss 1.9 [42]
Bacterial meningitis 1.5–1.7 [42]
Buccal mucosa penetration 1.5 [42]
Carotid puncture 0.77 [42]
PBC Hyperesthesia; persistent symptoms 89–100; 4.6–40 [41]
Masseter weakness 1.2–12 [39]
Facial hematoma 3.5–6.7 [43]
Hearing loss 2.4–6.3 [44]
Anesthesia dolorosa 0–3.4 [39]
Decreased corneal sensation 0–3.1 [40]
Pseudoaneurysm 1 [44]
Bacterial meningitis 0.7–1 [43]
Aseptic meningitis 0.7 [43]
Trigeminal reflex bradycardia
Hypotension
GKRS Hyperesthesia 6–42 [33]
Anesthesia dolorosa 0.2 [33]
MVD Trigeminal nerve deficit 1.6–22 [45]
Facial weakness 0.6–10.6 [45]
Hearing loss 1.2–6.8 [45]
Anesthesia dolorosa 0–4 [46]
Aseptic meningitis 2 [47]
Hydrocephalus 0.15 [48]
Mortality 0.15–0.8 [24]
Cerebellar infarct or hematoma 0.075–0.68 [45]
Table 1. 
Summary of complications and rates associated with PRR, PGR, PBC, GKRS, and MVD [24].
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5.3 Other treatment options for trigeminal neuralgia
5.3.1 Peripheral neurectomy
5.3.1.1 Indication
• Medically refractory trigeminal neuralgia in patients who are unable to 
undergo general anesthesia (frail, elderly, or medically unstable patients), as 
this can be performed as an outpatient procedure under local anesthesia [11]
• Therapeutic for patients reluctant to undergo major neurosurgery or have 
contraindications for craniotomy when rhizotomies are not possible [49]
• Rural settings where too large surgical facilities may be inaccessible
5.3.1.2 Contraindication
Peripheral neurectomy may be contraindicated in those unable to tolerate general 
anesthesia, as other approaches are more invasive (e.g., maxillary sinus route) [49].
5.3.1.3 Approach
For procedures done under local anesthesia, a diagnostic nerve block with 2% 
lidocaine HCl plus adrenaline 1:200,000 concentration must completely resolve 
symptoms prior to neurectomy [14]. Infraorbital, inferior alveolar, and mental 
neurectomies usually require the following incisions: vestibular, Ginwalla’s, and 
crevicular incision, respectively. Clamping and avulsion of the mental nerve require 
an additional Y-shaped incision along the anterior border of the ascending ramus. 
After further blunt and sharp dissection on its medial aspect, the temporalis and 
medial pterygoid muscles are split, facilitating the clamping and avulsing of the 
mental nerve at the mental foramen. Sealing the infraorbital foramen with stainless 
steel screws is the final step [14].
For procedures done under general anesthesia, patients are supine, and an intra-
oral mucoperiosteal incision is made between the buccal sulcus of the upper lateral 
incisor to the first molar on the symptomatic side [49]. Once the infraorbital fossa 
is exposed, access to the maxillary sinus is gained via bone window with a diameter 
of 2 cm in the anterior wall of the maxillary sinus. Further dissection completely 
Summary of outcomes
Procedure Initial response (%) rate 1-year 5-year 10-year 20-year
PRR 97.6–99 61.8 57.7 52.3 41
PGR 71–97.9 53–63 43.5
PBC 82–93.8 74.6 69.8 30–51.5
GKRS 79–91.8
(Delayed 10 days–3.4 months)
75–90 44–65 30–51.5
MVD 80.3–96 84 72–85 74
Table 2. 
Summary of success rates of PRR, PGR, PBC, GKRS, and MVD immediately following procedure, 1-, 5-, 10-, 
and 20-year time points [24].
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liberates the entire neurovascular bundle in the maxillary sinus, and the removal of 
the inferior bone of the infraorbital canal and fissure ensues [49]. Another round 
bone window with 1.5 cm diameter is made at the upper 1/3 of the posterior wall of 
the maxillary sinus with extreme care as injury to the maxillary artery may occur. 
The superior bony wall of the maxillary sinus is removed to expose the pterygopala-
tine fossa segment of the maxillary nerve. The length of the maxillary nerve from 
the infraorbital foramen to the pterygopalatine fossa is removed, along with the 
branches of the infraorbital nerve [49].
5.3.1.4 Complications
Anesthesia or paresthesia in the maxillary distribution postoperatively is com-
mon and short-lasting. The major complications regarding the pterygoid palatine 
fossa segment neurectomy of the maxillary nerve under general anesthesia are 
bleeding, infection, and eye or encephalic injuries.
5.3.1.5 Outcome
Pain relief from peripheral neurectomies has been reported to an average of 
26.5 months when obturated with fatty tissues [50] and greater than 24 months 
when obturated with stainless steel screws [14]. One case report from India of a 
65-year-old female who underwent a mental neurectomy endorsed pain reduc-
tion from 8 to 1 on VAS score from pre-procedure to 2 years postoperatively, 
respectively [11]. In terms of recurrence rate, a Danish study evaluated patients 
at a mean follow-up time of 7 years and reported 78% of patients experienced a 
recurrence, with half of this group becoming symptomatic within the first month 
[51]. A study that evaluated 40 patients treated with neurectomy, of whom 28 had 
previously undergone radiofrequency lesions, 5 of these patients had recurrence 
after 2 years and were successfully treated with repeat neurectomy [52]. Thus, it 
can be inferred that mean follow-up time for neurectomy patients in the setting 
of trigeminal neuralgia is incredibly variable, with sparse reliable data to support 
findings.
5.3.2 Botulinum toxin type-A (BTX-A) injections
5.3.2.1 Indications
• Medically refractory trigeminal neuralgia in patients who desire minimally 
invasive procedures or are unable to general anesthesia (frail, elderly, or medi-
cally unstable patients)
• Patients with contraindications to major neurosurgery
• Patient preference for minimally invasive procedure, as this can be performed 
outpatient without anesthesia [12]
5.3.2.2 Contraindications
Patients with pre-existing disease that may be exacerbated by exposure to 
BTX-A (e.g., myasthenia gravis, motor neuron disease, or Lambert-Eaton syn-
drome), superficial skin infection on treatment site, or the use of drug within 7 days 
of BTX-A injection that may adversely affect neuromuscular junction (e.g., quinine, 
aminoglycosides, and penicillamine) [12].
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5.3.2.3 Approach
The number of units and sites to be injected varies per patient. One study 
approach used a 0.5-mL syringe with 5-/16-inch, 30-gauge needle for subcutaneous 
injection [53]. Other studies describe injection of unstandardized dosages intramus-
cularly in the region of the zygomatic arch or masseter [54]. A randomized, double-
blind study showed no difference between 25 and 75 units, as both had sustained 
pain relief at 8 weeks postinjection [12]. Whereas, doses as large as 60 and 40 units 
of BTX-A diluted in 2.5-mL saline, administered to the external nasal trigger zone 
and right mental nerve region, respectively, showed sustained relief at 5 months [55].
5.3.2.4 Complications
As BTX-A injections are generally considered safe; few complications such as 
short-term (<6 weeks) asymmetry in the injection area during dynamic movement 
and transient facial edema (<5 days) have been noted [12]. In patients currently on a 
pharmacologic regimen for trigeminal neuralgia (either analgesic or prophylactic), 
no adverse effects were noted when combined with BTX-A injections [53].
5.3.2.5 Outcome
Adequate pain control in patients treated with BTX-A has varied between 
90 days [15] and 5 months [55]; however, results are largely based on case reports 
or studies with small sample size. One small, randomized, open-ended study with 
eight participants underwent BTX-A injections for intractable trigeminal neural-
gia found a mean baseline pain score of 4 on VAS, which was reduced to 1.19 at 
6 months following treatment [54]. Another study with 13 patients treated with 
BTX-A and followed at 10-, 20-, 30-, and 60-day postinjection reported pain relief 
and reduced need for pharmacotherapy in all patients over the course of their study 
[53]. However, this is often the case where follow-up periods in patients treated with 
BTX-A and other surgical interventions for their trigeminal neuralgia are not long 
enough to reliably deduce long-term efficacy.
5.3.3 Cryotherapy (cryoanalgesia)
5.3.3.1 Indications
• Medically refractory disease in patients limited to the supraorbital, infraor-
bital, and mental nerves and potentially the long buccal and lingual nerves
• Elderly or medically compromised patients who are unfit for surgery
• Patient preference for minimally invasive procedure [16]
5.3.3.2 Contraindications
Negligible contraindications have been reported.
5.3.3.3 Approach
Involved nerve branches are identified with test doses of local anesthesia. Upon 
complete pain abolition, cryotherapy blockades can proceed in an outpatient setting 
under local anesthesia and intravenous sedation [56].
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The approach to the inferior dental nerve cryoblockade utilizes C-arm radio-
graphic guidance, image intensifier, and nerve stimulator on the cryoprobe. Lateral 
oblique films confirm accurate needle placement prior to alcohol injection around 
the inferior dental nerve [16].
The approach of cryoblockade to other nerves such as the infraorbital, mental, 
and inferior alveolar nerves begins with the following incisions: intraoral Caldwell-
Luc, intraoral low buccal in the premolar region, and intraoral Ginwalla, respec-
tively. Exposed nerves are frozen with nitrous oxide via cryoprobe at a temperature 
of −700°C for 2-minute freezing cycles followed by 5 minutes of thawing. This is 
repeated three times [57].
5.3.3.4 Complications
Potential complications associated with cryoblockade are infection, swelling, 
trismus, and paresthesia ranging from complete numbness or altered sensation, up 
to 3 months postoperatively [56]. In a study with 145 patients treated with cryother-
apy, 58 patients experienced symptoms of atypical facial pain (symptoms described 
as burning, pins and needles, or dull ache) which responded to a short course of 
tricyclic antidepressants [58].
5.3.3.5 Outcome
Duration of pain relief ranges from 6 [56] to 20 months, depending on the 
treated nerve. A study that looked at 145 patients with paroxysmal trigeminal 
neuralgia treated with cryotherapy demonstrated a mean relief period of 13 months 
for long buccal nerve, 17 months for mental, and 20 months for infraorbital nerves 
[58]. Although well tolerated by patients, multiple sessions of cryotherapy may be 
needed to achieve durable pain relief, due to regenerative capacity of nerves, albeit 
subsequent injections are rarely as effective as the first [58]. In a study that looked 
at 145 patients treated by cryotherapy, 56% of patients needed more than 1 treat-
ment, with a number of patients needing up to 11 procedures. Of the 145 patients, 
pain relief at 6 months was achieved in half of the group, with only 27% pain-free 
at 1 year [58].
6. Conclusion
As medical treatment with anticonvulsants has been the cornerstone of first-line 
management of trigeminal neuralgia, surgical interventions have been developed 
for more involved cases. Patients who continue to experience pain with three 
failed drug trials or encounter an intolerable side-effect profile from medications 
are generally considered for surgical evaluation. However, only patients who are 
deemed surgically fit per medical status/age shall be recommended for operative 
procedures.
Diagnostic blocks are fundamental in the surgical evaluation of a patient with 
medically refractory trigeminal neuralgia. Trigeminal nerve and Gasserian ganglion 
blocks confirm the clinical diagnosis before the patient can be considered for sub-
sequent intervention. Additional nerve blocks administered to a terminal branch of 
the trigeminal nerve or at the Gasserian ganglion with therapeutic intent may offer 
adequate pain control for some patients. Most commonly, patients are treated with 
percutaneous rhizotomies (radiofrequency, glycerol, and balloon compression), 
stereotactic radiosurgery, and microvascular decompression for more sustained 
pain relief with minimal postoperative complications. Other procedures that have 
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fallen out of favor but are still used are peripheral neurectomy include botulinum 
toxin type-A injections and cryotherapy on a case-by-case basis. It is thought that 
patients opting for modalities targeting peripheral branches of the trigeminal 
nerve, rather than the ganglion or nerve root, are more likely to become symptom-
atic as pain may break through in other nerves not previously treated [59].
Ultimately, all surgical candidates are thoroughly counseled on available 
interventions and their individual risk-benefit profiles before undergoing further 
treatment. As all surgical techniques have demonstrated efficacy in the treatment of 
medically refractory trigeminal neuralgia, patient input on procedure invasiveness, 
repeatability, accessibility, and cost are all important factors to consider in choosing 
a treatment. More studies with larger sample size, randomized controlled design, 
and stricter diagnostic criteria for patients are needed to reliably comment on the 
prognostic value of each of the aforementioned treatment options. Regardless, it 
is with a patient-centric, multidisciplinary approach from all physicians involved 
in a patient’s care that the best treatment plan can be implemented for those with 
intractable trigeminal neuralgia.
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